SCHEMBL21144165

SCHEMBL21144165

COc1cnc(Cl)nc1NC1CCC(F)(F)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
TRPM8 Q7Z2W7 2/20 0.44
EHMT2 Q96KQ7 2/20 0.41
IDH1 O75874 4/20 0.41
EHMT1 Q9H9B1 1/20 0.40
IDH2 P48735 2/20 0.40
AXL P30530 1/20 0.39
MAPK8 P45983 2/20 0.37
WHR1 P49842 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SCN9A Q15858 1/20 0.36
LRRK2 Q5S007 1/20 0.36
GBA1 P04062 1/20 0.36
BCL6 P41182 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
MAPK3 P27361 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127257 1.00 KMT2A (0.47) KMT2ATRPM8EHMT2IDH1EHMT1
SCHEMBL3145566 0.87 KMT2A (0.51) KMT2ATRPM8EHMT2AXLKDM4E
SCHEMBL27196854 0.85 KMT2A (0.60) KMT2ATRPM8EHMT2EHMT1AXL
SCHEMBL12526913 0.81 NSD2 (0.46) KMT2ATRPM8EHMT2AXLALDH1A1
Hydrochloric Acid SCHEMBL1748440 0.80 NSD2 (0.46) KMT2ATRPM8EHMT2AXLALDH1A1
SCHEMBL19687464 0.79 KMT2A (0.47) KMT2AIDH1IDH2AXLMAPK8
SCHEMBL25902571 0.78 TRPM8 (0.41) KMT2ATRPM8EHMT2AXLKDM4E
SCHEMBL26627801 0.76 LRRK2 (0.45) KMT2ATRPM8EHMT2LRRK2
SCHEMBL30462044 0.76 LRRK2 (0.45) KMT2ATRPM8EHMT2LRRK2
SCHEMBL21143941 0.76 USP2 (0.46) KMT2AEHMT2IDH1EHMT1IDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KMT2A 1471/4885TRPM8 82/4885EHMT2 3277/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KMT2A 1471/4885TRPM8 82/4885EHMT2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.